AstraZeneca and Daiichi Sankyo’s Enhertu Delivers 14.3-Month PFS in HER2-Mutant NSCLC
Seoul, South Korea, September 14, 2026 AstraZeneca and Daiichi Sankyo announced positive results from the Phase III DESTINY-Lung04 trial,...
drug development
Advertisement
Avance Clinical Wins Australia-Taiwan Business Award
Taipei, Taiwan, September 11, 2026 Avance Clinical has received the Australia-Taiwan Business Excellence Award from the Australia New Zealand...
CONNECTA Therapeutics Secures €3.1M for Fragile X Program
BARCELONA, Spain — September 10, 2026 CONNECTA Therapeutics announced the closing of a €3.1 million financing led by new...
Teitur Trophics Advances TT-P34 Toward Phase II in Parkinson’s
AARHUS, Denmark — September 10, 2026 Teitur Trophics announced successful results from the Phase I clinical trial of TT-P34,...
EPIK Biosciences Expands Ketamine and DXM Drug Portfolio
AUSTIN, Texas — September 10, 2026 EPIK Biosciences announced continued progress in developing proprietary synergistic combination medicines targeting mental...
Advertisements
Kura Oncology launches Caspian Therapeutics with $50M financing
SAN DIEGO — September 9, 2026 Kura Oncology, Inc. announced the launch of Caspian Therapeutics, Inc., a separately financed...
Adagene and Exelixis Advance SAFEbody ADC Programs
San Diego, California, USA, and Suzhou, China, September 9, 2026 Adagene Inc. and Exelixis Inc. have achieved a new...
Eir Partners Acquires Accumulus to Scale Life Sciences
San Francisco, California, USA, September 9, 2026 Eir Partners has acquired Accumulus Technologies, marking a new phase of growth...
Evommune Reports Phase 2b Setback for EVO756 in Atopic Dermatitis
PALO ALTO, Calif. and NEW YORK — September 8, 2026 Evommune, Inc. announced top-line results from its randomized, double-blind,...
LUMA Vision Wins FDA Clearance for VERAFEYE Cardiac Platform
Dublin, Ireland, September 9, 2026 LUMA Vision has secured additional U.S. FDA clearance for its VERAFEYE™ procedural intelligence platform,...
Advertisement
